Skip to main content

Advertisement

Table 1 Site-level characteristics among patients with ≥ 1 visit after enrollment with CD4 ≥ 200 & WHO 1 or 2 at enrollment, MTCT-Plus Initiative, 2003-2008

From: Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative

Country/Site Total Females (%) Median (IQR) FU time1,2 Deaths (%) Withdrawals3 (%) LTF at 12mo2 (%) LTF at 24mo2 (%) LTF at the end of data collection2 (%)
Cote d' Ivoire 588 537 (91.3) 1.7 (0.7-3) 8 (1.4) 26 (4.4) 16 (3.5) 32 (8) 43 (13)
Kisumu, Kenya 304 257 (84.5) 1.5 (0.6-2.5) 7 (2.3) 11 (3.6) 58 (21.8) 89 (35.9) 105 (50.1)
Thailand 344 262 (76.2) 1.8 (0.8-2.9) 1 (0.3) 28 (8.1) 14 (4.9) 50 (20.7) 66 (33.3)
Nsambya, Uganda 387 297 (76.7) 2.1 (1.1-3.2) 4 (1) 14 (3.6) 3 (0.9) 11 (4) 22 (11.6)
Zambia 501 443 (88.4) 1.4 (0.7-2.6) 7 (1.4) 49 (9.8) 86 (19.5) 130 (32.8) 149 (45.8)
Soweto, S.A. 496 445 (89.7) 2.7 (1–3.6) 7 (1.4) 39 (8.8) 29 (6.8) 57 (14.1) 91 (26.2)
Cato Manor, S.A. 450 406 (90.2) 1.2 (0.4-2.3) 9 (2) 140 (31.1) 33 (10) 44 (14.9) 48 (19.5)
Rwanda 191 145 (75.9) 2 (1–3.4) 1 (0.5) 13 (6.8) 16 (9.5) 28 (17.9) 44 (39)
Eldoret, Kenya 286 244 (85.3) 1.8 (0.4-3.5) 1 (0.3) 2 (0.7) 17 (7.7) 25 (12) 43 (31.2)
Mulago, Uganda 331 232 (70.1) 3.1 (1.5-3.8) 9 (2.7) 11 (3.3) 1 (0.3) 4 (1.5) 6 (4)
Cameroon 400 345 (86.3) 1.2 (0.6-1.8) 4 (1) 15 (3.8) 16 (5.3) 23 (8.6) 24 (10)
Total 4278 3613 (84.5) 1.7 (0.7-3) 58 (1.4) 348 (8.1) 289 (8.2) 493 (15.6) 641 (26.4)
  1. 1In years, excluding patients with no follow-up
  2. 2Using Kaplan-Meier product limit estimation method. Patients whose last visit was > 12 months prior to the end of data collection are considered LTF. Patients who are LTF are considered lost 90 days after their last visit
  3. 3Includes transfers